An Open-Label, Randomized, Crossover Trial utilizing a Single-Blinded Rater to evaluate APL-130277 compared to s.c. Apomorphine in Levodopa Responsive Subjects with Parkinson's Disease Complicated by Motor Fluctuations
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 06 Mar 2018
At a glance
- Drugs Apomorphine (Primary)
- Indications Parkinson's disease
- Focus Registrational; Therapeutic Use
- Sponsors Sunovion Pharmaceuticals
- 27 Feb 2018 Planned initiation date changed from 22 Jan 2018 to 1 May 2018.
- 16 Jan 2018 Planned initiation date changed from 3 Jan 2018 to 22 Jan 2018.
- 21 Oct 2017 Planned number of patients changed from 150 to 85.